Menu Search
Equities

Asiri Surgical Hospital PLC

AMSL.N0000:CSE

Asiri Surgical Hospital PLC

Actions
Health CareHealth Care Providers
  • Price (LKR)11.50
  • Today's Change0.20 / 1.77%
  • Shares traded6.04k
  • 1 Year change-4.17%
  • Beta--
Data delayed at least 15 minutes, as of May 31 2024.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Asiri Surgical Hospital PLC is a Sri Lanka-based healthcare provider. The Company provides a complete range of services through technology. The Company operates through three segments: Pre care, Post care, and Pharmaceutical. The Pre care segment is engaged in the outpatient department (OPD) lab investigation services. The Post care segment provides all inpatient department (IPD), including inpatient drugs and lab investigation. The Pharmaceutical segment includes OPD pharmacy. It has various centers, including Asiri-Heart Center, Brain and Spine Center, Stroke Unit, Cosmetic Center, Urology Unit, Blood Cancer & Bone Marrow Transplant Center, Interventional Radiology, Vaccination Clinic, and Kidney Transplant center. Its health and wellness services provide wellness centers, breast care center, well women’s clinic, audiology unit, sleep study, psychology, elderly care service, mindfulness center, among others.

  • Revenue in LKR (TTM)6.54bn
  • Net income in LKR497.11m
  • Incorporated2000
  • Employees362.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.